Abingworth

Chicago, Illinois

Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs to develop their ideas into products that have a dramatic impact on health. With over $1 billion under management, Abingworth invests at all stages of development, from start-ups to publicly traded companies, and across all life sciencessectors. Supporting its portfolio companies with a team of 27 at offices in London, Menlo Park, and Boston, Abingworth has invested in 142 life science companies, completed 60 IPOs and 40 mergers and acquisitions.

Founded:1973

Firm Location:Chicago, Illinois • San Francisco, California • Boston, Massachusetts • Menlo Park, California • London

Abingworth Team

INVESTORS	INTRO STRENGTH	SWEET SPOT (RANGE)	INVESTMENT LOCATIONS	TOP INVESTMENT CATEGORIES
Scott Brun AbingworthVenture Partner	n/a	$22.5M ($15.0M - $30.0M)	Investors in Boston (MA)	Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series A), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series A), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in Health IT (Seed), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in Pharmaceuticals (Series A), Investors in Health & Hospital Services (Series A), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in Pharmaceuticals (Series B), Investors in Health & Hospital Services (Series B), Investors in Midwest (Other Lists), Investors in Boston / New England (Other Lists), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Digital Health (Series B), Investors in Digital Health (Series B), Investors in Health IT (Seed), Investors in Health IT (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed) +28
Lucille Conroy AbingworthPrincipal	n/a	$22.5M ($15.0M - $30.0M)	Investors in United Kingdom, Investors in London	Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in BioTech (Seed), Investors in Health IT (Seed), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Seed), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in London (Other Lists), Investors in Health IT (Seed), Investors in Health & Hospital Services (Seed) +8
Jay Cui AbingworthPrincipal	n/a	$22.5M ($15.0M - $30.0M)	Investors in Menlo Park (CA)	Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in Health & Hospital Services (Series B), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in BioTech (Seed), Investors in Health IT (Seed), Investors in Health & Hospital Services (Series A), Investors in San Francisco Bay Area (Other Lists), Investors in Health & Hospital Services (Seed), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Seed), Investors in Health IT (Series B), Investors in Health & Hospital Services (Seed) +14
Kurt von Emster AbingworthManaging Partner	n/a	$22.5M ($15.0M - $30.0M)	Investors in Menlo Park (CA)	Investors in BioTech (Series B), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in San Francisco Bay Area (Other Lists), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B) +9
Brian Gallagher AbingworthPartner	n/a	$22.5M ($15.0M - $30.0M)	Investors in Boston (MA)	Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series B), Investors in Pharmaceuticals (Series B), Investors in Boston / New England (Other Lists) +9
Jacqueline Grant AbingworthPrincipal	n/a	$22.5M ($15.0M - $30.0M)	Investors in Boston (MA)	Investors in BioTech (Series A), Investors in BioTech (Series A), Investors in Boston / New England (Other Lists)
Ken Haas AbingworthInvestor	n/a	$22.5M ($15.0M - $30.0M)	Investors in San Francisco (CA)	Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in San Francisco Bay Area (Other Lists), Investors in BioTech (Series A)
Timothy Haines AbingworthManaging Partner	n/a	$22.5M ($15.0M - $30.0M)	Investors in London	Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in London (Other Lists) +4
Genghis Lloyd-Harris AbingworthPartner	n/a	$22.5M ($15.0M - $30.0M)	Investors in London	Investors in BioTech (Series B), Investors in Medical Devices (Series B), Investors in Medical Devices (Series A), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in Medical Devices (Series A), Investors in Health & Hospital Services (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in Medical Devices (Series B), Investors in Pharmaceuticals (Series B), Investors in Health & Hospital Services (Series B), Investors in London (Other Lists), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series B), Investors in Health IT (Series B) +21
Diya Malhotra AbingworthInvestor	n/a	$22.5M ($15.0M - $30.0M)	Investors in London	Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series A), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in London (Other Lists) +4
Vincent Miles AbingworthPartner	n/a	$22.5M ($15.0M - $30.0M)	Investors in Boston (MA)	Investors in BioTech (Series B), Investors in Pharmaceuticals (Series B), Investors in BioTech (Series B), Investors in Pharmaceuticals (Series B), Investors in Boston / New England (Other Lists) +1
Bali Muralidhar AbingworthManaging Partner	n/a	$22.5M ($15.0M - $30.0M)	Investors in London	Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in BioTech (Seed), Investors in Health IT (Seed), Investors in Health & Hospital Services (Series A), Investors in Pharmaceuticals (Seed), Investors in Health & Hospital Services (Seed), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Pharmaceuticals (Series A), Investors in London (Other Lists), Investors in Health IT (Seed), Investors in Health & Hospital Services (Seed) +12
Jayson Punwani AbingworthPartner	n/a	$22.5M ($15.0M - $30.0M)	Investors in SF Bay Area (CA)	Investors in Medical Devices (Seed), Investors in BioTech (Series B), Investors in Medical Devices (Series B), Investors in Medical Devices (Series A), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in Medical Devices (Seed), Investors in San Francisco Bay Area (Other Lists), Investors in BioTech (Series A), Investors in Medical Devices (Series A), Investors in BioTech (Series B), Investors in Medical Devices (Series B), Investors in Diagnostics (Seed), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Series B), Investors in Diagnostics (Seed), Investors in Diagnostics (Series A), Investors in Digital Health (Series B), Investors in Digital Health (Seed), Investors in Digital Health (Series A), Investors in Digital Health (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed) +20
Andrew Sinclair AbingworthPartner	n/a	$22.5M ($15.0M - $30.0M)	Investors in London	Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in London (Other Lists) +4